U.S., April 17 -- ClinicalTrials.gov registry received information related to the study (NCT06929286) titled 'A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)' on April 14.
Brief Summary: The purpose of this study is to compare the effectiveness of different FDA-approved/NCCN-recommended drug treatments for NMIBC. In particular, the FDA-approved drug nadofaragene firadenovec will be compared to usual care with other NCCN-recommended standard treatments for NMIBC (gemcitabine with or without docetaxel, mitomycin, re-treatment with BCG, or pembrolizumab).
Study Start Date: April 11
Study Type: INTERVENTIONAL
Condition:
Non-Muscle Invasive Bladder Cancer
Intervention:
DRUG: Nadofaragene Fir...